文献速递胸部肿瘤

胸部CT肺癌筛查的获益与危害:系统评价与荟萃分析

Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2021-06-02

该荟萃分析纳入9项随机试验共88497例吸烟者,比较CT肺癌筛查与不筛查或胸片。CT筛查显著降低肺癌死亡率(总体RR 0.87,95%CI 0.78-0.98),增加早期肿瘤诊断和可切除率,但过度诊断率显著增加(不筛查组38%,95%CI 14-63)。全因死亡率无显著降低。

要点

  • CT肺癌筛查可显著降低吸烟者肺癌相关死亡率。
  • CT筛查增加早期肿瘤诊断率和可切除率,减少晚期诊断。
  • 过度诊断率显著增加,需权衡获益与危害。

核心结论

  • 在吸烟者中,CT肺癌筛查的获益超过危害,支持系统实施肺癌筛查。

研究设计与样本

  • 系统评价与荟萃分析,纳入9项随机试验共88497例吸烟者。

主要发现

  • 肺癌相关死亡率总体RR 0.87(95%CI 0.78-0.98),不筛查组RR 0.80(95%CI 0.69-0.92)。
  • 早期肿瘤诊断总体RR 2.84(95%CI 1.76-4.58),不筛查组RR 3.33(95%CI 2.27-4.89),胸片组RR 1.52(95%CI 1.04-2.23)。
  • 晚期肿瘤诊断总体RR 0.75(95%CI 0.68-0.83),不筛查组RR 0.67(95%CI 0.56-0.80)。
  • 可切除率不筛查组RR 2.57(95%CI 1.76-3.74)。
  • 全因死亡率总体RR 0.99(95%CI 0.94-1.05),过度诊断率不筛查组38%(95%CI 14-63)。

临床怎么用

  • 对有吸烟史的人群可考虑采用胸部CT进行肺癌筛查。

局限性

  • 过度诊断估计仍存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This meta-analysis aims to combine and analyze randomized clinical trials comparing computed tomography lung screening (CTLS) versus either no screening (NS) or chest x-ray (CXR) in subjects with cigarette smoking history, to provide a precise and reliable estimation of the benefits and harms associated with CTLS. MATERIALS AND METHODS: Data from all published randomized trials comparing CTLS versus either NS or CXR in a highly tobacco-exposed population were collected, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Subgroup analyses by comparator (NS or CXR) were performed. Pooled risk ratio (RR) and relative 95% CIs were calculated for dichotomous outcomes. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Nine eligible trials (88,497 patients) were included. Pooled analysis showed that CTLS is associated with: a significant reduction of lung cancer-related mortality (overall RR, 0.87; 95% CI, 0.78 to 0.98; NS RR, 0.80; 95% CI, 0.69 to 0.92); a significant increase of early-stage tumors diagnosis (overall RR, 2.84; 95% CI 1.76 to 4.58; NS RR, 3.33; 95% CI, 2.27 to 4.89; CXR RR, 1.52; 95% CI, 1.04 to 2.23); a significant decrease of late-stage tumors diagnosis (overall RR, 0.75; 95% CI, 0.68 to 0.83; NS RR, 0.67; 95% CI, 0.56 to 0.80); a significant increase of resectability rate (NS RR, 2.57; 95% CI, 1.76 to 3.74); a nonsignificant reduction of all-cause mortality (overall RR, 0.99; 95% CI, 0.94 to 1.05); and a significant increase of overdiagnosis rate (NS, 38%; 95% CI, 14 to 63). The analysis of lung cancer-related mortality by sex revealed nonsignificant differences between men and women (P = .21; I-squared = 33.6%). CONCLUSION: Despite there still being uncertainty about overdiagnosis estimate, this meta-analysis suggested that the CTLS benefits outweigh harms, in subjects with cigarette smoking history, ultimately supporting the systematic implementation of lung cancer screening worldwide.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Passiglia F, Cinquini M, Bertolaccini L, et al. Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021. PMID: 34236916. doi:10.1200/JCO.20.02574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。